| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:52:04 UTC |
|---|
| HMDB ID | HMDB0015678 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Nepafenac |
|---|
| Description | Nepafenac, also known as nevanac or ahr 9434, belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups. After penetrating the cornea as a prodrug, nepafenac undergoes rapid bioactivation to amfenac, which is a potent NSAID that uniformly inhibits the COX1 and COX2 activity. Nepafenac (prodrug) is deaminated to amfenac (active compound) in the ciliary body epithelium, retina, and choroid by intraocular hydrolases. Nepafenac is a drug which is used for the treatment of pain and inflammation associated with cataract surgery. Ocularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is used to treat pain and inflammation associated with cataract surgery. The mean steady-state Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 0.422 ± 0.121 ng/ml, respectively, following ocular administration. Nepafenac is a moderately basic compound (based on its pKa). In humans, nepafenac is involved in nepafenac action pathway. Nepafenac is only found in individuals that have used or taken this drug. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation. |
|---|
| Structure | NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Amino-3-benzoylbenzeneacetamide | ChEBI | | AHR 9434 | ChEBI | | AHR-9434 | ChEBI | | AL 6515 | ChEBI | | AL-6515 | ChEBI | | Nepafenaco | ChEBI | | Nepafenacum | ChEBI | | Nevanac | ChEBI | | Amfenac amide | HMDB |
|
|---|
| Chemical Formula | C15H14N2O2 |
|---|
| Average Molecular Weight | 254.2839 |
|---|
| Monoisotopic Molecular Weight | 254.105527702 |
|---|
| IUPAC Name | 2-(2-amino-3-benzoylphenyl)acetamide |
|---|
| Traditional Name | nepafenac |
|---|
| CAS Registry Number | 78281-72-8 |
|---|
| SMILES | NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N |
|---|
| InChI Identifier | InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18) |
|---|
| InChI Key | QEFAQIPZVLVERP-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Benzophenones |
|---|
| Direct Parent | Benzophenones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzophenone
- Aryl-phenylketone
- Diphenylmethane
- Phenylacetamide
- Benzoyl
- Aniline or substituted anilines
- Aryl ketone
- Vinylogous amide
- Amino acid or derivatives
- Carboxamide group
- Primary carboxylic acid amide
- Ketone
- Carboxylic acid derivative
- Amine
- Organonitrogen compound
- Organooxygen compound
- Primary amine
- Hydrocarbon derivative
- Organic oxide
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.52 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.7824 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.87 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 35.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1605.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 311.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 138.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 188.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 103.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 379.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 453.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 128.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 983.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 372.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1137.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 307.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 340.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 301.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 310.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 92.0 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Nepafenac,1TMS,isomer #1 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N | 2521.5 | Semi standard non polar | 33892256 | | Nepafenac,1TMS,isomer #1 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N | 2614.2 | Standard non polar | 33892256 | | Nepafenac,1TMS,isomer #1 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N | 3483.4 | Standard polar | 33892256 | | Nepafenac,1TMS,isomer #2 | C[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1 | 2529.4 | Semi standard non polar | 33892256 | | Nepafenac,1TMS,isomer #2 | C[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1 | 2492.6 | Standard non polar | 33892256 | | Nepafenac,1TMS,isomer #2 | C[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1 | 3444.3 | Standard polar | 33892256 | | Nepafenac,2TMS,isomer #1 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C | 2553.5 | Semi standard non polar | 33892256 | | Nepafenac,2TMS,isomer #1 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C | 2634.7 | Standard non polar | 33892256 | | Nepafenac,2TMS,isomer #1 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C | 3089.1 | Standard polar | 33892256 | | Nepafenac,2TMS,isomer #2 | C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C | 2579.6 | Semi standard non polar | 33892256 | | Nepafenac,2TMS,isomer #2 | C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C | 2676.5 | Standard non polar | 33892256 | | Nepafenac,2TMS,isomer #2 | C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C | 3359.2 | Standard polar | 33892256 | | Nepafenac,2TMS,isomer #3 | C[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C | 2529.4 | Semi standard non polar | 33892256 | | Nepafenac,2TMS,isomer #3 | C[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C | 2538.5 | Standard non polar | 33892256 | | Nepafenac,2TMS,isomer #3 | C[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C | 3262.3 | Standard polar | 33892256 | | Nepafenac,3TMS,isomer #1 | C[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C)[Si](C)(C)C)C=CC=C1C(=O)C1=CC=CC=C1 | 2631.8 | Semi standard non polar | 33892256 | | Nepafenac,3TMS,isomer #1 | C[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C)[Si](C)(C)C)C=CC=C1C(=O)C1=CC=CC=C1 | 2700.4 | Standard non polar | 33892256 | | Nepafenac,3TMS,isomer #1 | C[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C)[Si](C)(C)C)C=CC=C1C(=O)C1=CC=CC=C1 | 2980.6 | Standard polar | 33892256 | | Nepafenac,3TMS,isomer #2 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C | 2563.2 | Semi standard non polar | 33892256 | | Nepafenac,3TMS,isomer #2 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C | 2585.5 | Standard non polar | 33892256 | | Nepafenac,3TMS,isomer #2 | C[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C | 2906.3 | Standard polar | 33892256 | | Nepafenac,4TMS,isomer #1 | C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2641.7 | Semi standard non polar | 33892256 | | Nepafenac,4TMS,isomer #1 | C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2720.9 | Standard non polar | 33892256 | | Nepafenac,4TMS,isomer #1 | C[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2809.1 | Standard polar | 33892256 | | Nepafenac,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N | 2726.8 | Semi standard non polar | 33892256 | | Nepafenac,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N | 2805.7 | Standard non polar | 33892256 | | Nepafenac,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N | 3523.1 | Standard polar | 33892256 | | Nepafenac,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1 | 2748.6 | Semi standard non polar | 33892256 | | Nepafenac,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1 | 2713.9 | Standard non polar | 33892256 | | Nepafenac,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1 | 3519.9 | Standard polar | 33892256 | | Nepafenac,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C(C)(C)C | 2961.4 | Semi standard non polar | 33892256 | | Nepafenac,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C(C)(C)C | 3024.6 | Standard non polar | 33892256 | | Nepafenac,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N[Si](C)(C)C(C)(C)C | 3263.5 | Standard polar | 33892256 | | Nepafenac,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C(C)(C)C | 3012.2 | Semi standard non polar | 33892256 | | Nepafenac,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C(C)(C)C | 3078.7 | Standard non polar | 33892256 | | Nepafenac,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N)[Si](C)(C)C(C)(C)C | 3398.9 | Standard polar | 33892256 | | Nepafenac,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C(C)(C)C | 2979.8 | Semi standard non polar | 33892256 | | Nepafenac,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C(C)(C)C | 2930.4 | Standard non polar | 33892256 | | Nepafenac,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N(C1=C(CC(N)=O)C=CC=C1C(=O)C1=CC=CC=C1)[Si](C)(C)C(C)(C)C | 3351.4 | Standard polar | 33892256 | | Nepafenac,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=CC=C1C(=O)C1=CC=CC=C1 | 3227.5 | Semi standard non polar | 33892256 | | Nepafenac,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=CC=C1C(=O)C1=CC=CC=C1 | 3287.7 | Standard non polar | 33892256 | | Nepafenac,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=C(CC(=O)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=CC=C1C(=O)C1=CC=CC=C1 | 3241.8 | Standard polar | 33892256 | | Nepafenac,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3171.0 | Semi standard non polar | 33892256 | | Nepafenac,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3192.8 | Standard non polar | 33892256 | | Nepafenac,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3179.0 | Standard polar | 33892256 | | Nepafenac,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3473.8 | Semi standard non polar | 33892256 | | Nepafenac,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3477.0 | Standard non polar | 33892256 | | Nepafenac,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3126.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Nepafenac GC-MS (Non-derivatized) - 70eV, Positive | splash10-03di-1490000000-472a61bcbe3904de6ac4 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Nepafenac GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Nepafenac GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Nepafenac , positive-QTOF | splash10-03dr-1490000000-433d63cd52e5b86417da | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 10V, Positive-QTOF | splash10-0a4r-0190000000-b6c2bf9435ad635d30bf | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 20V, Positive-QTOF | splash10-0a4r-0890000000-1c148620fd1183334640 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 40V, Positive-QTOF | splash10-0a4i-2900000000-de52c273376f27e1aec8 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 10V, Negative-QTOF | splash10-0udi-0090000000-1410eafe17e767b3cc39 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 20V, Negative-QTOF | splash10-0w2c-3290000000-3604d63c0fc47c406ecc | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 40V, Negative-QTOF | splash10-0006-9200000000-0ccf405a700b155ba243 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 10V, Positive-QTOF | splash10-0a4i-0090000000-3060c6f1d3f25782b5f6 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 20V, Positive-QTOF | splash10-06si-0970000000-521792df462056dc0554 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 40V, Positive-QTOF | splash10-004i-9400000000-b292dc56c56def4c3cc1 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 10V, Negative-QTOF | splash10-0ik9-0090000000-db943419dc26289ab4fe | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 20V, Negative-QTOF | splash10-03di-0090000000-409cecc16290d2050d37 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nepafenac 40V, Negative-QTOF | splash10-0006-9540000000-5ae94d44ecaaabdcabf9 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [PubMed:10850857 ]
- Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [PubMed:10850858 ]
- Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8. [PubMed:17189793 ]
- Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45. [PubMed:17720067 ]
- Bucci FA Jr, Waterbury LD: Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. doi: 10.1016/j.jcrs.2008.05.019. [PubMed:18655957 ]
- Summary Basis of Decision (SBD): NEVANAC. [Link]
|
|---|